Postcards from Bangalore
Last week, we had the good fortune of spending a week in India, along with our colleagues from Ventac Partners. Our trip took us through the cities of Mumbai,…
Menu
Top 10 Drug Products in India
Do you know which are the top branded drug products in India? We didn't until we found this handy chart and article. We took their IMS data a step…
Indian pharma draws more FDA scrutiny
We've posted about the Indian pharmaceutical market before, but this report is downright shocking: U.S. inspectors visiting a factory in India owned by drugmaker Wockhardt Ltd in March…
Biocon Mylan Biogenerics Partnership
Today we learn that generics giant Mylan has entered into a partnership with India-based Biocon to focus on insulin analog biosimilars: Under the terms of this collaboration, Mylan will have…
Pfizer Biocon signals the end for biosimilars? Hardly…
Earlier this week we learned that Pfizer will return to Biocon rights to biosimilar versions of various insulin derivatives: As of March 12, 2012, all rights licensed to Pfizer will…
The Sandwich Shoppe is Closed
There has been a lot of commentary this week on Pfizer's announcement that their highly respected research center in Sandwich, UK, will be closed. The original press release suggested that…
More Government Involvement in Pharma Industry
The past few months have seen a number of reports describing how national governments are using policy to spur local pharmaceutical industry growth. We have already described examples from Brazil,…
More on Russia…Is the US Next?
Last week we wrote about the Russian government's desire to grow their national pharmaceutical infrastructure. Our reading of the situation is that the government will "suggest" that ex-Russia companies who…
India, India, and more about India
Here is a sample of announcements from today alone regarding the pharmaceutical industry in India: First, UK-based Reckitt Benckiser is acquiring Paras Pharmaceuticals for $726 million. Paras makes a variety…
The Indian Connection
The Indian pharmaceutical market is highly fragmented. How can pharma companies make money? PharmaTimes characterizes the market for us in summary form.